粒子線治療市場:タイプ別(陽子線治療、重粒子線治療)、製品別(サイクロトロン、シンクロトロン、シンクロサイクロトロン)、サービス別、システム別(シングルルーム、マルチルーム)、がんタイプ別(小児がん、前立腺がん)、用途別(治療、研究)-2028年までの世界予測Particle Therapy Market by Type (Proton Therapy, Heavy Ion), Products (Cyclotron, Synchrotron, Synchrocyclotron), Services, System (Single-room, Multi-room), Cancer Type (Pediatric, Prostate), Application (Treatment, Research) - Global Forecast to 2028 世界の粒子線治療市場は、2023年の7億米ドルから2028年には11億米ドルに達し、予測期間中のCAGRは8.2%で成長すると予測されている。粒子線治療市場の急成長が予測される背景には、がんの増加、技術の進歩、がん... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリー世界の粒子線治療市場は、2023年の7億米ドルから2028年には11億米ドルに達し、予測期間中のCAGRは8.2%で成長すると予測されている。粒子線治療市場の急成長が予測される背景には、がんの増加、技術の進歩、がんに関する個人の意識の向上、がん研究への資金提供の増加などがある。「2023年から2028年の予測期間において、小児アプリケーション分野が最も高いCAGRを記録する。 粒子線治療市場は、がんの種類に基づき、小児がん、乳がん、肺がん、前立腺がん、頭頸部がん、その他のがんに区分される。2022年には小児がんが最も高い成長率を示している。小児がんの増加は、遺伝的素因、乳幼児の発育要因、未熟な免疫系、環境暴露、母親の要因、細胞の脆弱性などが原因となっている。 "アジア太平洋地域は予測期間中に市場の著しい成長率を記録する" 予測期間2023-2028年において、APAC地域は予測期間中に市場で著しい成長率を記録すると予想される。アジア太平洋地域は、インド、中国、日本、オーストラリア、韓国、RoAPACで構成される。アジア太平洋(APAC)地域は、粒子線治療市場の市場成長率が大幅に上昇している。この成長にはいくつかの要因がある: APAC諸国では人口動態が成熟しつつあり、治療関連の副作用を最小限に抑えた効率的ながん治療法が求められている。粒子線治療市場の精密さ主導の特性との共鳴は、市場展望を拡大する上で極めて重要な役割を果たしている。 APACの病院では多言語による患者ケアを提供しており、粒子線治療市場のような先進治療へのアクセスも容易であることから、この地域は特に多様な患者の間で独特の魅力を放っている。このような言語的な包括性と最先端の医療介入の融合は、この地域の好まれている医療目的地としての望ましさを著しく高め、その結果、医療市場ランドスケープにおける競争力を強化し、粒子線治療市場の隆盛を後押ししている。 本レポートの主な参加企業の内訳は以下の通りである: - 企業タイプ別ティア1-40%、ティア2-30%、ティア3-30 - 役職別Cレベル-27%、ディレクターレベル-18%、その他-55 - 地域別北米-50%、欧州-20%、アジア太平洋地域-15%、中南米-10%、中東・アフリカ-5 粒子線治療市場の主要企業は、Varian Medical Systems, Inc.(米国)、IBA Worldwide(EU)、日立製作所(日本)などである。 調査範囲 - 本レポートでは、粒子線治療市場をタイプ、システム、製品、用途、癌タイプ、地域に基づいて調査しています。 - 市場成長に影響を与える要因(促進要因、阻害要因、機会、課題など)を分析しています。 - 利害関係者向けに市場の機会と課題を評価し、市場リーダー向けに競争環境の詳細を提供しています。 - 微小市場の成長動向、展望、世界の粒子線治療市場への貢献に関して調査しています。 - 主要5地域に関して市場セグメントの収益を予測しています。 レポート購入の主な利点 本レポートは、包括的なデータの徹底的な分析を通じて、粒子線治療市場における投資評価の実行可能性について、市場リーダー/新規参入企業/小規模企業の助けとなり、それによって強固なリスク評価が容易になり、十分な情報に基づいた投資決定が可能になります。用途、エンドユーザー、地域などの次元を網羅した綿密な市場区分により、的確なセグメントターゲティングのためのテーラーメイドの洞察が得られます。また、極めて重要なトレンド、成長触媒、課題、展望を網羅的に評価し、鋭い洞察力で戦略的意思決定を後押しします。 本レポートは、以下のポイントに関する洞察を提供しています: - 粒子線治療市場の成長に影響を与える主な促進要因(がん患者人口の増加、がん管理に対する政府の取り組みの増加、放射線治療による非侵襲的治療の進歩)、阻害要因(熟練した放射線科医/腫瘍医の不足、粒子線治療の高コスト、治療のための画像技術の複雑さ)、機会(新興国における主要企業の拡大、発展途上国における医療費の増加)、課題(代替技術の利用可能性)についての分析を掲載しています。 - 製品開発/イノベーション:粒子線治療市場における今後の技術、研究開発活動、新製品・サービスの発売に関する詳細な洞察。 - 市場開発:有利な市場に関する包括的情報 - 当レポートでは、さまざまな地域の粒子線治療市場を分析しています。 - 市場の多様化:粒子線治療市場における新製品、未開拓地域、最近の開発、投資に関する詳細な情報 - 競合評価:Varian Medical Systems社(米国)、IBA Worldwide社(EU)、日立製作所(日本)などの主要企業の市場シェア、成長戦略、サービス内容を詳細に評価。 目次1 INTRODUCTION 281.1 STUDY OBJECTIVES 28 1.2 MARKET DEFINITION 28 1.3 INCLUSIONS & EXCLUSIONS 29 1.4 MARKET SCOPE 29 1.4.1 MARKETS COVERED 29 1.4.2 REGIONS COVERED 30 1.4.3 YEARS CONSIDERED 30 1.4.4 CURRENCY CONSIDERED 31 TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 31 1.5 STAKEHOLDERS 31 1.6 SUMMARY OF CHANGES 31 1.6.1 RECESSION IMPACT: PARTICLE THERAPY MARKET 32 2 RESEARCH METHODOLOGY 33 2.1 RESEARCH DATA 33 FIGURE 1 RESEARCH DESIGN 33 2.1.1 SECONDARY DATA 33 2.1.1.1 Key data from secondary sources 34 2.1.2 PRIMARY DATA 35 2.1.2.1 Key primary sources 35 2.1.2.2 Key data from primary sources 36 2.1.2.3 Breakdown of primaries 36 FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 36 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY END USER, DESIGNATION, AND REGION 37 2.1.2.4 Key industry insights 37 2.2 MARKET SIZE ESTIMATION 38 FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2022 39 FIGURE 5 SUPPLY-SIDE ANALYSIS 39 FIGURE 6 TOP-DOWN APPROACH 40 FIGURE 7 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 41 FIGURE 8 CAGR PROJECTIONS 42 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 43 FIGURE 9 DATA TRIANGULATION METHODOLOGY 43 2.4 RESEARCH LIMITATIONS 44 2.4.1 SCOPE-RELATED LIMITATIONS 44 2.4.2 METHODOLOGY-RELATED LIMITATIONS 44 2.5 RISK ASSESSMENT 44 2.6 STUDY ASSUMPTIONS 45 2.6.1 IMPACT OF RECESSION ON PARTICLE THERAPY MARKET 45 3 EXECUTIVE SUMMARY 46 FIGURE 10 PARTICLE THERAPY MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 46 FIGURE 11 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 47 FIGURE 12 PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 47 FIGURE 13 PARTICLE THERAPY MARKET, BY SYSTEM, 2023 VS. 2028 (USD MILLION) 48 FIGURE 14 PARTICLE THERAPY MARKET, BY CANCER TYPE, 2023 VS. 2028 (USD MILLION) 49 FIGURE 15 PARTICLE THERAPY MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 49 FIGURE 16 GEOGRAPHICAL SNAPSHOT OF PARTICLE THERAPY MARKET 50 4 PREMIUM INSIGHTS 51 4.1 PARTICLE THERAPY MARKET OVERVIEW 51 FIGURE 17 INCREASING PREVALENCE OF CANCER TO DRIVE MARKET 51 4.2 REGIONAL MIX: PARTICLE THERAPY MARKET 52 FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD 52 4.3 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY TYPE AND COUNTRY (2022) 53 FIGURE 19 PROTON THERAPY ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2022 53 4.4 PARTICLE THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 54 FIGURE 20 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 54 4.5 DEVELOPED VS. EMERGING ECONOMIES: PARTICLE THERAPY MARKET 54 FIGURE 21 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 54 5 MARKET OVERVIEW 55 5.1 INTRODUCTION 55 FIGURE 22 PARTICLE THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 55 5.1.1 DRIVERS 56 5.1.1.1 Advantages of particle therapy over photon therapy 56 5.1.1.2 Growing prevalence of cancer 56 5.1.1.3 Rising adoption of particle therapy in clinical trials 57 5.1.1.4 Increasing number of particle therapy centers worldwide 57 5.1.1.5 Technological advancements 57 5.1.2 RESTRAINTS 58 5.1.2.1 Infrastructural challenges in healthcare facilities 58 5.1.2.2 Affordability and accessibility of treatments 58 5.1.2.3 Unfavorable reimbursement policies and limited insurance coverage for particle therapy 59 5.1.3 OPPORTUNITIES 59 5.1.3.1 Growth potential of emerging economies 59 5.1.4 CHALLENGES 60 5.1.4.1 Difficulties in visualizing tumors during particle therapy procedures 60 5.1.4.2 Potential for unwanted radiation exposure 60 5.2 ECOSYSTEM/MARKET MAP 61 FIGURE 23 PARTICLE THERAPY MARKET: ECOSYSTEM ANALYSIS 61 5.3 PRICING ANALYSIS 61 5.4 SUPPLY CHAIN ANALYSIS 62 FIGURE 24 SUPPLY CHAIN ANALYSIS: PARTICLE THERAPY MARKET 62 5.5 PATENT ANALYSIS 63 5.5.1 PATENT PUBLICATION TRENDS FOR PARTICLE THERAPY MARKET 63 FIGURE 25 TOTAL PATENTS GRANTED FROM 2012–2022 64 FIGURE 26 TOP PATENT APPLICANTS IN PARTICLE THERAPY 64 FIGURE 27 TOP PATENT OWNERS IN PARTICLE THERAPY 65 5.6 VALUE CHAIN ANALYSIS 65 FIGURE 28 PARTICLE THERAPY MARKET: VALUE CHAIN ANALYSIS 66 5.7 TECHNOLOGY ANALYSIS 66 5.8 KEY CONFERENCES & EVENTS IN 2023–2024 67 5.9 REGULATORY LANDSCAPE 68 TABLE 2 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68 TABLE 3 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68 TABLE 4 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69 TABLE 5 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69 TABLE 6 REGULATORY STANDARDS/APPROVALS REQUIRED FOR PARTICLE THERAPY PRODUCTS BY COUNTRY/REGION 70 5.10 REIMBURSEMENT ANALYSIS 70 TABLE 7 MEDICAL REIMBURSEMENT CODES FOR PARTICLE THERAPY PROCEDURES IN US, 2022 70 5.11 TRADE ANALYSIS 71 TABLE 8 INSTALLED BASE OF RADIOTHERAPY DEVICES 71 5.12 PORTER’S FIVE FORCES ANALYSIS 71 TABLE 9 PARTICLE THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 71 5.12.1 THREAT OF NEW ENTRANTS 71 5.12.2 THREAT OF SUBSTITUTES 72 5.12.3 BARGAINING POWER OF SUPPLIERS 72 5.12.4 BARGAINING POWER OF BUYERS 72 5.12.5 DEGREE OF COMPETITION 72 5.13 KEY STAKEHOLDERS & BUYING CRITERIA 72 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 72 FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS 72 TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS (%) 73 5.13.2 BUYING CRITERIA 73 FIGURE 30 KEY BUYING CRITERIA FOR TOP THREE APPLICATIONS 73 TABLE 11 KEY BUYING CRITERIA FOR TOP THREE APPLICATIONS 73 5.14 CASE STUDY ANALYSIS 74 TABLE 12 CASE STUDY: ENHANCING PATIENT SAFETY—RT’S ROLE IN MINIMIZING RADIATION RISK IN AN ELDERLY PATIENT (90-YEAR-OLD FEMALE WITH A MEDICALLY INOPERABLE EARLY-STAGE NSCLC) 74 5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 74 FIGURE 31 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX 74 6 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE 75 6.1 INTRODUCTION 76 TABLE 13 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 76 6.2 PRODUCTS 76 TABLE 14 PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 76 TABLE 15 PARTICLE THERAPY PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 77 6.2.1 CYCLOTRONS 77 6.2.1.1 Advantages offered by cyclotrons over other accelerators to drive market 77 TABLE 16 CYCLOTRONS MARKET, BY REGION, 2021–2028 (USD MILLION) 78 TABLE 17 NORTH AMERICA: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 78 TABLE 18 EUROPE: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 78 TABLE 19 ASIA PACIFIC: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 79 TABLE 20 LATIN AMERICA: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 79 6.2.2 SYNCHROTRONS 79 6.2.2.1 Increasing investments for development of synchrotron facilities to aid market growth 79 TABLE 21 SYNCHROTRONS MARKET, BY REGION, 2021–2028 (USD MILLION) 80 TABLE 22 NORTH AMERICA: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 80 TABLE 23 EUROPE: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 80 TABLE 24 ASIA PACIFIC: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 81 TABLE 25 LATIN AMERICA: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 81 6.2.3 SYNCHROCYCLOTRONS 81 6.2.3.1 High space requirements to limit adoption 81 TABLE 26 SYNCHROCYCLOTRONS MARKET, BY REGION, 2021–2028 (USD MILLION) 82 TABLE 27 NORTH AMERICA: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 82 TABLE 28 EUROPE: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 83 TABLE 29 ASIA PACIFIC: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 83 TABLE 30 LATIN AMERICA: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84 6.3 SERVICES 84 6.3.1 AVAILABILITY OF WIDE RANGE OF SERVICES TO PROPEL MARKET 84 TABLE 31 PARTICLE THERAPY SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 84 TABLE 32 NORTH AMERICA: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85 TABLE 33 EUROPE: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85 TABLE 34 ASIA PACIFIC: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86 TABLE 35 LATIN AMERICA: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86 7 PARTICLE THERAPY MARKET, BY TYPE 87 7.1 INTRODUCTION 88 TABLE 36 PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 88 7.2 PROTON THERAPY 88 7.2.1 GROWING ADOPTION AS PRIMARY TREATMENT FOR VARIOUS CANCER TYPES TO DRIVE MARKET 88 TABLE 37 PROTON THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 89 7.3 HEAVY ION THERAPY 89 7.3.1 SLOWER GROWTH ATTRIBUTED TO EXPERIMENTAL PHASE ACROSS MANY REGIONS 89 TABLE 38 HEAVY ION THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 90 8 PARTICLE THERAPY MARKET, BY SYSTEM 91 8.1 INTRODUCTION 92 TABLE 39 PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION) 92 8.2 MULTI-ROOM SYSTEMS 92 8.2.1 LOWER SHIELDING REQUIREMENTS AND FASTER BEAM-SWITCHING CAPABILITIES TO DRIVE INTEREST AMONG END USERS 92 TABLE 40 PARTICLE THERAPY MARKET FOR MULTI-ROOM SYSTEMS, BY REGION, 2021–2028 (USD MILLION) 93 8.3 SINGLE-ROOM SYSTEMS 93 8.3.1 COMPACT STRUCTURE AND REDUCED CAPITAL COST TO PROPEL GROWTH 93 TABLE 41 PARTICLE THERAPY MARKET FOR SINGLE-ROOM SYSTEMS, BY REGION, 2021–2028 (USD MILLION) 94 9 PARTICLE THERAPY MARKET, BY APPLICATION 95 9.1 INTRODUCTION 96 TABLE 42 PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 96 9.2 TREATMENT APPLICATIONS 96 9.2.1 INTRODUCTION OF SMALL FOOTPRINT SINGLE-ROOM PARTICLE THERAPY CENTERS TO SUPPORT MARKET GROWTH 96 TABLE 43 PARTICLE THERAPY MARKET FOR TREATMENT APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 97 9.3 RESEARCH APPLICATIONS 97 9.3.1 INCREASING AVAILABILITY OF FUNDING FOR PARTICLE THERAPY-RELATED RESEARCH PROJECTS TO PROVIDE GROWTH OPPORTUNITIES 97 TABLE 44 PARTICLE THERAPY MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 98 10 PARTICLE THERAPY MARKET, BY CANCER TYPE 99 10.1 INTRODUCTION 100 TABLE 45 PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION) 100 10.2 PEDIATRIC CANCER 100 10.2.1 INCREASING CASES OF PEDIATRIC CANCER TO PROPEL MARKET 100 TABLE 46 PARTICLE THERAPY MARKET FOR PEDIATRIC CANCER, BY REGION, 2021–2028 (USD MILLION) 101 10.3 PROSTATE CANCER 101 10.3.1 ADVANTAGES OFFERED BY PARTICLE THERAPY FOR TREATMENT OF PROSTATE CANCER TO DRIVE MARKET 101 TABLE 47 PARTICLE THERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2021–2028 (USD MILLION) 102 10.4 LUNG CANCER 102 10.4.1 GROWING CLINICAL TESTING OF PROTON THERAPY FOR LUNG CANCER TO DRIVE MARKET 102 TABLE 48 PARTICLE THERAPY MARKET FOR LUNG CANCER, BY REGION, 2021–2028 (USD MILLION) 102 10.5 BREAST CANCER 103 10.5.1 LIMITED RADIATION EXPOSURE WITH REDUCED SIDE-EFFECTS TO INCREASE ADOPTION OF PARTICLE THERAPY 103 TABLE 49 PARTICLE THERAPY MARKET FOR BREAST CANCER, BY REGION, 2021–2028 (USD MILLION) 103 10.6 HEAD & NECK CANCER 103 10.6.1 USE OF PENCIL-BEAM SCANNING FOR PROTON THERAPY TO SUPPORT MARKET GROWTH 103 TABLE 50 PARTICLE THERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 2021–2028 (USD MILLION) 104 10.7 OTHER CANCERS 104 TABLE 51 PARTICLE THERAPY MARKET FOR OTHER CANCERS, BY REGION, 2021–2028 (USD MILLION) 104 11 PARTICLE THERAPY MARKET, BY REGION 105 11.1 INTRODUCTION 106 TABLE 52 PARTICLE THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 106 11.2 NORTH AMERICA 106 11.2.1 NORTH AMERICA: RECESSION IMPACT 106 FIGURE 32 NORTH AMERICA: PARTICLE THERAPY MARKET SNAPSHOT 107 TABLE 53 NORTH AMERICA: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108 TABLE 54 NORTH AMERICA: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 108 TABLE 55 NORTH AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 108 TABLE 56 NORTH AMERICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 109 TABLE 57 NORTH AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION) 109 TABLE 58 NORTH AMERICA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION) 109 TABLE 59 NORTH AMERICA: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 110 11.2.2 US 110 11.2.2.1 Growing number of particle therapy centers to drive market growth 110 TABLE 60 US: MACROECONOMIC INDICATORS 111 TABLE 61 US: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 111 TABLE 62 US: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 111 11.2.3 CANADA 112 11.2.3.1 Government initiative to include particle therapy as treatment method to boost market 112 TABLE 63 CANADA: MACROECONOMIC INDICATORS 112 TABLE 64 CANADA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 113 TABLE 65 CANADA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 113 11.3 EUROPE 113 11.3.1 EUROPE: RECESSION IMPACT 114 TABLE 66 EUROPE: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114 TABLE 67 EUROPE: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 114 TABLE 68 EUROPE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 115 TABLE 69 EUROPE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 115 TABLE 70 EUROPE: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION) 115 TABLE 71 EUROPE: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION) 116 TABLE 72 EUROPE: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 116 11.3.2 GERMANY 116 11.3.2.1 Increasing research on proton and heavy ion therapy to drive market growth 116 TABLE 73 GERMANY: MACROECONOMIC INDICATORS 117 TABLE 74 GERMANY: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 117 TABLE 75 GERMANY: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 117 11.3.3 FRANCE 118 11.3.3.1 Increasing healthcare expenditure to support particle therapy product adoption 118 TABLE 76 FRANCE: MACROECONOMIC INDICATORS 118 TABLE 77 FRANCE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 119 TABLE 78 FRANCE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 119 11.3.4 UK 119 11.3.4.1 Increasing acceptance of particle therapy techniques in cancer treatment to support market growth 119 TABLE 79 UK: MACROECONOMIC INDICATORS 120 TABLE 80 UK: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 120 TABLE 81 UK: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 121 11.3.5 ITALY 121 11.3.5.1 Increasing awareness activities to support market growth 121 TABLE 82 ITALY: MACROECONOMIC INDICATORS 121 TABLE 83 ITALY: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 122 TABLE 84 ITALY: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 122 11.3.6 SPAIN 122 11.3.6.1 Increasing number of conferences and government funding for cancer research to drive market 122 TABLE 85 SPAIN: MACROECONOMIC INDICATORS 123 TABLE 86 SPAIN: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 124 TABLE 87 SPAIN: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 124 11.3.7 REST OF EUROPE 124 TABLE 88 REST OF EUROPE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 125 TABLE 89 REST OF EUROPE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 125 11.4 ASIA PACIFIC 125 11.4.1 ASIA PACIFIC: RECESSION IMPACT 126 FIGURE 33 ASIA PACIFIC: PARTICLE THERAPY MARKET SNAPSHOT 127 TABLE 90 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128 TABLE 91 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 128 TABLE 92 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 128 TABLE 93 ASIA PACIFIC: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 129 TABLE 94 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION) 129 TABLE 95 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION) 129 TABLE 96 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 130 11.4.2 JAPAN 130 11.4.2.1 Increasing use of heavy ion therapy for cancer treatment to propel market 130 TABLE 97 JAPAN: MACROECONOMIC INDICATORS 131 TABLE 98 JAPAN: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 131 TABLE 99 JAPAN: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 131 11.4.3 CHINA 132 11.4.3.1 High cancer burden to drive market 132 TABLE 100 CHINA: MACROECONOMIC INDICATORS 132 TABLE 101 CHINA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 133 TABLE 102 CHINA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 133 11.4.4 INDIA 133 11.4.4.1 Improving research capabilities to support market growth 133 TABLE 103 INDIA: MACROECONOMIC INDICATORS 134 TABLE 104 INDIA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 134 TABLE 105 INDIA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 134 11.4.5 AUSTRALIA 135 11.4.5.1 Healthcare funding availability to boost market growth 135 TABLE 106 AUSTRALIA: MACROECONOMIC INDICATORS 135 TABLE 107 AUSTRALIA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 135 TABLE 108 AUSTRALIA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 136 11.4.6 SOUTH KOREA 136 11.4.6.1 Rising prevalence of cancer to drive market 136 TABLE 109 SOUTH KOREA: MACROECONOMIC INDICATORS 137 TABLE 110 SOUTH KOREA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 137 TABLE 111 SOUTH KOREA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 137 11.4.7 REST OF ASIA PACIFIC 138 TABLE 112 REST OF ASIA PACIFIC: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 138 TABLE 113 REST OF ASIA PACIFIC: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 138 11.5 LATIN AMERICA 139 11.5.1 LATIN AMERICA: RECESSION IMPACT 139 TABLE 114 LATIN AMERICA: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 139 TABLE 115 LATIN AMERICA: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 140 TABLE 116 LATIN AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 140 TABLE 117 LATIN AMERICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 140 TABLE 118 LATIN AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION) 141 TABLE 119 LATIN AMERICA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION) 141 TABLE 120 LATIN AMERICA: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 141 11.5.2 BRAZIL 142 11.5.2.1 Government initiates to propel market growth 142 TABLE 121 BRAZIL: MACROECONOMIC INDICATORS 142 TABLE 122 BRAZIL: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 143 TABLE 123 BRAZIL: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 143 11.5.3 MEXICO 143 11.5.3.1 Growing adoption of advanced medical technologies to drive market 143 TABLE 124 MEXICO: MACROECONOMIC INDICATORS 144 TABLE 125 MEXICO: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 144 TABLE 126 MEXICO: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 144 11.5.4 REST OF LATIN AMERICA 145 TABLE 127 REST OF LATIN AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 145 TABLE 128 REST OF LATIN AMERICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 145 11.6 MIDDLE EAST & AFRICA 146 11.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET 146 11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 146 TABLE 129 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 147 TABLE 130 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 147 TABLE 131 MIDDLE EAST & AFRICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 147 TABLE 132 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION) 148 TABLE 133 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION) 148 TABLE 134 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 148 12 COMPETITIVE LANDSCAPE 149 12.1 OVERVIEW 149 12.2 STRATEGIES ADOPTED BY KEY PLAYERS 150 FIGURE 34 KEY DEVELOPMENTS IN PARTICLE THERAPY MARKET 150 12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 151 FIGURE 35 REVENUE ANALYSIS OF TOP PLAYERS IN PARTICLE THERAPY MARKET 151 12.4 MARKET SHARE ANALYSIS 152 FIGURE 36 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022 152 12.5 COMPANY EVALUATION MATRIX 153 12.5.1 STARS 153 12.5.2 EMERGING LEADERS 153 12.5.3 PERVASIVE PLAYERS 153 12.5.4 PARTICIPANTS 153 FIGURE 37 PARTICLE THERAPY MARKET: COMPANY EVALUATION MATRIX, 2022 154 12.6 COMPETITIVE BENCHMARKING FOR KEY PLAYERS 155 12.6.1 PARTICLE THERAPY MARKET: COMPANY FOOTPRINT 155 TABLE 135 OVERALL COMPANY FOOTPRINT (10 COMPANIES) 155 TABLE 136 TYPE FOOTPRINT (10 COMPANIES) 155 TABLE 137 PRODUCT & SERVICE FOOTPRINT (10 COMPANIES) 156 TABLE 138 SYSTEM FOOTPRINT (10 COMPANIES) 157 TABLE 139 CANCER TYPE FOOTPRINT (10 COMPANIES) 157 TABLE 140 APPLICATION FOOTPRINT (10 COMPANIES) 158 TABLE 141 REGIONAL FOOTPRINT (10 COMPANIES) 159 12.7 STARTUP/SME EVALUATION MATRIX 160 12.7.1 PROGRESSIVE COMPANIES 160 12.7.2 RESPONSIVE COMPANIES 160 12.7.3 DYNAMIC COMPANIES 160 12.7.4 STARTING BLOCKS 160 FIGURE 38 PARTICLE THERAPY MARKET: STARTUP/SME EVALUATION MATRIX, 2022 161 12.7.5 COMPETITIVE BENCHMARKING FOR STARTUPS/SMES 162 TABLE 142 OVERALL COMPANY FOOTPRINT 162 TABLE 143 TYPE FOOTPRINT 162 TABLE 144 PRODUCT & SERVICE FOOTPRINT 162 TABLE 145 SYSTEM FOOTPRINT 163 TABLE 146 CANCER TYPE FOOTPRINT 163 TABLE 147 APPLICATION FOOTPRINT 163 TABLE 148 REGIONAL FOOTPRINT 163 12.8 COMPETITIVE SCENARIOS & TRENDS 164 12.8.1 PRODUCT LAUNCHES & APPROVALS 164 TABLE 149 PARTICLE THERAPY MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020−AUGUST 2023) 164 12.8.2 DEALS 164 TABLE 150 PARTICLE THERAPY MARKET: DEALS (JANUARY 2020−AUGUST 2023) 164 12.8.3 OTHER DEVELOPMENTS 166 TABLE 151 PARTICLE THERAPY MARKET: OTHER DEVELOPMENTS (JANUARY 2020−AUGUST 2023) 166 13 COMPANY PROFILES 167 13.1 KEY PLAYERS 167 (Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)* 13.1.1 IBA WORLDWIDE 167 TABLE 152 IBA WORLDWIDE: BUSINESS OVERVIEW 167 FIGURE 39 IBA WORLDWIDE: COMPANY SNAPSHOT (2022) 168 13.1.2 VARIAN MEDICAL SYSTEMS, INC. 172 TABLE 153 VARIAN MEDICAL SYSTEMS, INC.: BUSINESS OVERVIEW 172 FIGURE 40 VARIAN MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2022) 173 13.1.3 HITACHI, LTD. 176 TABLE 154 HITACHI, LTD.: BUSINESS OVERVIEW 176 FIGURE 41 HITACHI, LTD.: COMPANY SNAPSHOT (2021) 177 13.1.4 MEVION MEDICAL SYSTEMS 179 TABLE 155 MEVION MEDICAL SYSTEMS: BUSINESS OVERVIEW 179 13.1.5 SUMITOMO HEAVY INDUSTRIES LTD. 182 TABLE 156 SUMITOMO HEAVY INDUSTRIES LTD.: BUSINESS OVERVIEW 182 FIGURE 42 SUMITOMO HEAVY INDUSTRIES LTD.: COMPANY SNAPSHOT (2021) 183 13.1.6 PROVISION HEALTHCARE, LLC 185 TABLE 157 PROVISION HEALTHCARE, LLC: BUSINESS OVERVIEW 185 13.1.7 TOSHIBA MEDICAL SYSTEMS CORPORATION 186 TABLE 158 TOSHIBA MEDICAL SYSTEMS CORPORATION: BUSINESS OVERVIEW 186 FIGURE 43 TOSHIBA MEDICAL SYSTEMS CORPORATION: COMPANY SNAPSHOT (2022) 187 13.1.8 OPTIVUS PROTON THERAPY, INC. 188 TABLE 159 OPTIVUS PROTON THERAPY, INC.: BUSINESS OVERVIEW 188 13.1.9 PROTOM INTERNATIONAL, INC. 189 TABLE 160 PROTOM INTERNATIONAL, INC.: BUSINESS OVERVIEW 189 13.1.10 ADVANCED ONCOTHERAPY PLC 190 TABLE 161 ADVANCED ONCOTHERAPY PLC: BUSINESS OVERVIEW 190 13.2 OTHER PLAYERS 191 13.2.1 DANFYSIK A/S 191 TABLE 162 DANFYSIK A/S: BUSINESS OVERVIEW 191 13.2.2 P-CURE, LTD. 192 TABLE 163 P-CURE, LTD.: BUSINESS OVERVIEW 192 13.2.3 PTW FREIBURG GMBH 193 TABLE 164 PTW FREIBURG GMBH: BUSINESS OVERVIEW 193 *Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies. 14 APPENDIX 194 14.1 DISCUSSION GUIDE 194 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 199 14.3 CUSTOMIZATION OPTIONS 201 14.4 RELATED REPORTS 201 14.5 AUTHOR DETAILS 202
SummaryThe global particle therapy market is projected to reach USD 1.1 billion by 2028 from USD 0.7 billion in 2023, growing at a CAGR of 8.2% during the forecast period. The projected surge in market growth for the Particle therapy market is seen due to an increase in cancers, advancements in technologies, and increased awareness among individuals regarding cancer, Increased funding for cancer research. Table of Contents1 INTRODUCTION 281.1 STUDY OBJECTIVES 28 1.2 MARKET DEFINITION 28 1.3 INCLUSIONS & EXCLUSIONS 29 1.4 MARKET SCOPE 29 1.4.1 MARKETS COVERED 29 1.4.2 REGIONS COVERED 30 1.4.3 YEARS CONSIDERED 30 1.4.4 CURRENCY CONSIDERED 31 TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 31 1.5 STAKEHOLDERS 31 1.6 SUMMARY OF CHANGES 31 1.6.1 RECESSION IMPACT: PARTICLE THERAPY MARKET 32 2 RESEARCH METHODOLOGY 33 2.1 RESEARCH DATA 33 FIGURE 1 RESEARCH DESIGN 33 2.1.1 SECONDARY DATA 33 2.1.1.1 Key data from secondary sources 34 2.1.2 PRIMARY DATA 35 2.1.2.1 Key primary sources 35 2.1.2.2 Key data from primary sources 36 2.1.2.3 Breakdown of primaries 36 FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 36 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY END USER, DESIGNATION, AND REGION 37 2.1.2.4 Key industry insights 37 2.2 MARKET SIZE ESTIMATION 38 FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2022 39 FIGURE 5 SUPPLY-SIDE ANALYSIS 39 FIGURE 6 TOP-DOWN APPROACH 40 FIGURE 7 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 41 FIGURE 8 CAGR PROJECTIONS 42 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 43 FIGURE 9 DATA TRIANGULATION METHODOLOGY 43 2.4 RESEARCH LIMITATIONS 44 2.4.1 SCOPE-RELATED LIMITATIONS 44 2.4.2 METHODOLOGY-RELATED LIMITATIONS 44 2.5 RISK ASSESSMENT 44 2.6 STUDY ASSUMPTIONS 45 2.6.1 IMPACT OF RECESSION ON PARTICLE THERAPY MARKET 45 3 EXECUTIVE SUMMARY 46 FIGURE 10 PARTICLE THERAPY MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 46 FIGURE 11 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 47 FIGURE 12 PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 47 FIGURE 13 PARTICLE THERAPY MARKET, BY SYSTEM, 2023 VS. 2028 (USD MILLION) 48 FIGURE 14 PARTICLE THERAPY MARKET, BY CANCER TYPE, 2023 VS. 2028 (USD MILLION) 49 FIGURE 15 PARTICLE THERAPY MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 49 FIGURE 16 GEOGRAPHICAL SNAPSHOT OF PARTICLE THERAPY MARKET 50 4 PREMIUM INSIGHTS 51 4.1 PARTICLE THERAPY MARKET OVERVIEW 51 FIGURE 17 INCREASING PREVALENCE OF CANCER TO DRIVE MARKET 51 4.2 REGIONAL MIX: PARTICLE THERAPY MARKET 52 FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD 52 4.3 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY TYPE AND COUNTRY (2022) 53 FIGURE 19 PROTON THERAPY ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2022 53 4.4 PARTICLE THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 54 FIGURE 20 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 54 4.5 DEVELOPED VS. EMERGING ECONOMIES: PARTICLE THERAPY MARKET 54 FIGURE 21 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 54 5 MARKET OVERVIEW 55 5.1 INTRODUCTION 55 FIGURE 22 PARTICLE THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 55 5.1.1 DRIVERS 56 5.1.1.1 Advantages of particle therapy over photon therapy 56 5.1.1.2 Growing prevalence of cancer 56 5.1.1.3 Rising adoption of particle therapy in clinical trials 57 5.1.1.4 Increasing number of particle therapy centers worldwide 57 5.1.1.5 Technological advancements 57 5.1.2 RESTRAINTS 58 5.1.2.1 Infrastructural challenges in healthcare facilities 58 5.1.2.2 Affordability and accessibility of treatments 58 5.1.2.3 Unfavorable reimbursement policies and limited insurance coverage for particle therapy 59 5.1.3 OPPORTUNITIES 59 5.1.3.1 Growth potential of emerging economies 59 5.1.4 CHALLENGES 60 5.1.4.1 Difficulties in visualizing tumors during particle therapy procedures 60 5.1.4.2 Potential for unwanted radiation exposure 60 5.2 ECOSYSTEM/MARKET MAP 61 FIGURE 23 PARTICLE THERAPY MARKET: ECOSYSTEM ANALYSIS 61 5.3 PRICING ANALYSIS 61 5.4 SUPPLY CHAIN ANALYSIS 62 FIGURE 24 SUPPLY CHAIN ANALYSIS: PARTICLE THERAPY MARKET 62 5.5 PATENT ANALYSIS 63 5.5.1 PATENT PUBLICATION TRENDS FOR PARTICLE THERAPY MARKET 63 FIGURE 25 TOTAL PATENTS GRANTED FROM 2012–2022 64 FIGURE 26 TOP PATENT APPLICANTS IN PARTICLE THERAPY 64 FIGURE 27 TOP PATENT OWNERS IN PARTICLE THERAPY 65 5.6 VALUE CHAIN ANALYSIS 65 FIGURE 28 PARTICLE THERAPY MARKET: VALUE CHAIN ANALYSIS 66 5.7 TECHNOLOGY ANALYSIS 66 5.8 KEY CONFERENCES & EVENTS IN 2023–2024 67 5.9 REGULATORY LANDSCAPE 68 TABLE 2 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68 TABLE 3 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68 TABLE 4 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69 TABLE 5 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69 TABLE 6 REGULATORY STANDARDS/APPROVALS REQUIRED FOR PARTICLE THERAPY PRODUCTS BY COUNTRY/REGION 70 5.10 REIMBURSEMENT ANALYSIS 70 TABLE 7 MEDICAL REIMBURSEMENT CODES FOR PARTICLE THERAPY PROCEDURES IN US, 2022 70 5.11 TRADE ANALYSIS 71 TABLE 8 INSTALLED BASE OF RADIOTHERAPY DEVICES 71 5.12 PORTER’S FIVE FORCES ANALYSIS 71 TABLE 9 PARTICLE THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 71 5.12.1 THREAT OF NEW ENTRANTS 71 5.12.2 THREAT OF SUBSTITUTES 72 5.12.3 BARGAINING POWER OF SUPPLIERS 72 5.12.4 BARGAINING POWER OF BUYERS 72 5.12.5 DEGREE OF COMPETITION 72 5.13 KEY STAKEHOLDERS & BUYING CRITERIA 72 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 72 FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS 72 TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS (%) 73 5.13.2 BUYING CRITERIA 73 FIGURE 30 KEY BUYING CRITERIA FOR TOP THREE APPLICATIONS 73 TABLE 11 KEY BUYING CRITERIA FOR TOP THREE APPLICATIONS 73 5.14 CASE STUDY ANALYSIS 74 TABLE 12 CASE STUDY: ENHANCING PATIENT SAFETY—RT’S ROLE IN MINIMIZING RADIATION RISK IN AN ELDERLY PATIENT (90-YEAR-OLD FEMALE WITH A MEDICALLY INOPERABLE EARLY-STAGE NSCLC) 74 5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 74 FIGURE 31 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX 74 6 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE 75 6.1 INTRODUCTION 76 TABLE 13 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 76 6.2 PRODUCTS 76 TABLE 14 PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 76 TABLE 15 PARTICLE THERAPY PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 77 6.2.1 CYCLOTRONS 77 6.2.1.1 Advantages offered by cyclotrons over other accelerators to drive market 77 TABLE 16 CYCLOTRONS MARKET, BY REGION, 2021–2028 (USD MILLION) 78 TABLE 17 NORTH AMERICA: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 78 TABLE 18 EUROPE: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 78 TABLE 19 ASIA PACIFIC: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 79 TABLE 20 LATIN AMERICA: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 79 6.2.2 SYNCHROTRONS 79 6.2.2.1 Increasing investments for development of synchrotron facilities to aid market growth 79 TABLE 21 SYNCHROTRONS MARKET, BY REGION, 2021–2028 (USD MILLION) 80 TABLE 22 NORTH AMERICA: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 80 TABLE 23 EUROPE: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 80 TABLE 24 ASIA PACIFIC: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 81 TABLE 25 LATIN AMERICA: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 81 6.2.3 SYNCHROCYCLOTRONS 81 6.2.3.1 High space requirements to limit adoption 81 TABLE 26 SYNCHROCYCLOTRONS MARKET, BY REGION, 2021–2028 (USD MILLION) 82 TABLE 27 NORTH AMERICA: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 82 TABLE 28 EUROPE: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 83 TABLE 29 ASIA PACIFIC: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 83 TABLE 30 LATIN AMERICA: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84 6.3 SERVICES 84 6.3.1 AVAILABILITY OF WIDE RANGE OF SERVICES TO PROPEL MARKET 84 TABLE 31 PARTICLE THERAPY SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 84 TABLE 32 NORTH AMERICA: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85 TABLE 33 EUROPE: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85 TABLE 34 ASIA PACIFIC: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86 TABLE 35 LATIN AMERICA: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86 7 PARTICLE THERAPY MARKET, BY TYPE 87 7.1 INTRODUCTION 88 TABLE 36 PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 88 7.2 PROTON THERAPY 88 7.2.1 GROWING ADOPTION AS PRIMARY TREATMENT FOR VARIOUS CANCER TYPES TO DRIVE MARKET 88 TABLE 37 PROTON THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 89 7.3 HEAVY ION THERAPY 89 7.3.1 SLOWER GROWTH ATTRIBUTED TO EXPERIMENTAL PHASE ACROSS MANY REGIONS 89 TABLE 38 HEAVY ION THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 90 8 PARTICLE THERAPY MARKET, BY SYSTEM 91 8.1 INTRODUCTION 92 TABLE 39 PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION) 92 8.2 MULTI-ROOM SYSTEMS 92 8.2.1 LOWER SHIELDING REQUIREMENTS AND FASTER BEAM-SWITCHING CAPABILITIES TO DRIVE INTEREST AMONG END USERS 92 TABLE 40 PARTICLE THERAPY MARKET FOR MULTI-ROOM SYSTEMS, BY REGION, 2021–2028 (USD MILLION) 93 8.3 SINGLE-ROOM SYSTEMS 93 8.3.1 COMPACT STRUCTURE AND REDUCED CAPITAL COST TO PROPEL GROWTH 93 TABLE 41 PARTICLE THERAPY MARKET FOR SINGLE-ROOM SYSTEMS, BY REGION, 2021–2028 (USD MILLION) 94 9 PARTICLE THERAPY MARKET, BY APPLICATION 95 9.1 INTRODUCTION 96 TABLE 42 PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 96 9.2 TREATMENT APPLICATIONS 96 9.2.1 INTRODUCTION OF SMALL FOOTPRINT SINGLE-ROOM PARTICLE THERAPY CENTERS TO SUPPORT MARKET GROWTH 96 TABLE 43 PARTICLE THERAPY MARKET FOR TREATMENT APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 97 9.3 RESEARCH APPLICATIONS 97 9.3.1 INCREASING AVAILABILITY OF FUNDING FOR PARTICLE THERAPY-RELATED RESEARCH PROJECTS TO PROVIDE GROWTH OPPORTUNITIES 97 TABLE 44 PARTICLE THERAPY MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 98 10 PARTICLE THERAPY MARKET, BY CANCER TYPE 99 10.1 INTRODUCTION 100 TABLE 45 PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION) 100 10.2 PEDIATRIC CANCER 100 10.2.1 INCREASING CASES OF PEDIATRIC CANCER TO PROPEL MARKET 100 TABLE 46 PARTICLE THERAPY MARKET FOR PEDIATRIC CANCER, BY REGION, 2021–2028 (USD MILLION) 101 10.3 PROSTATE CANCER 101 10.3.1 ADVANTAGES OFFERED BY PARTICLE THERAPY FOR TREATMENT OF PROSTATE CANCER TO DRIVE MARKET 101 TABLE 47 PARTICLE THERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2021–2028 (USD MILLION) 102 10.4 LUNG CANCER 102 10.4.1 GROWING CLINICAL TESTING OF PROTON THERAPY FOR LUNG CANCER TO DRIVE MARKET 102 TABLE 48 PARTICLE THERAPY MARKET FOR LUNG CANCER, BY REGION, 2021–2028 (USD MILLION) 102 10.5 BREAST CANCER 103 10.5.1 LIMITED RADIATION EXPOSURE WITH REDUCED SIDE-EFFECTS TO INCREASE ADOPTION OF PARTICLE THERAPY 103 TABLE 49 PARTICLE THERAPY MARKET FOR BREAST CANCER, BY REGION, 2021–2028 (USD MILLION) 103 10.6 HEAD & NECK CANCER 103 10.6.1 USE OF PENCIL-BEAM SCANNING FOR PROTON THERAPY TO SUPPORT MARKET GROWTH 103 TABLE 50 PARTICLE THERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 2021–2028 (USD MILLION) 104 10.7 OTHER CANCERS 104 TABLE 51 PARTICLE THERAPY MARKET FOR OTHER CANCERS, BY REGION, 2021–2028 (USD MILLION) 104 11 PARTICLE THERAPY MARKET, BY REGION 105 11.1 INTRODUCTION 106 TABLE 52 PARTICLE THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 106 11.2 NORTH AMERICA 106 11.2.1 NORTH AMERICA: RECESSION IMPACT 106 FIGURE 32 NORTH AMERICA: PARTICLE THERAPY MARKET SNAPSHOT 107 TABLE 53 NORTH AMERICA: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108 TABLE 54 NORTH AMERICA: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 108 TABLE 55 NORTH AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 108 TABLE 56 NORTH AMERICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 109 TABLE 57 NORTH AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION) 109 TABLE 58 NORTH AMERICA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION) 109 TABLE 59 NORTH AMERICA: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 110 11.2.2 US 110 11.2.2.1 Growing number of particle therapy centers to drive market growth 110 TABLE 60 US: MACROECONOMIC INDICATORS 111 TABLE 61 US: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 111 TABLE 62 US: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 111 11.2.3 CANADA 112 11.2.3.1 Government initiative to include particle therapy as treatment method to boost market 112 TABLE 63 CANADA: MACROECONOMIC INDICATORS 112 TABLE 64 CANADA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 113 TABLE 65 CANADA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 113 11.3 EUROPE 113 11.3.1 EUROPE: RECESSION IMPACT 114 TABLE 66 EUROPE: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114 TABLE 67 EUROPE: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 114 TABLE 68 EUROPE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 115 TABLE 69 EUROPE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 115 TABLE 70 EUROPE: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION) 115 TABLE 71 EUROPE: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION) 116 TABLE 72 EUROPE: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 116 11.3.2 GERMANY 116 11.3.2.1 Increasing research on proton and heavy ion therapy to drive market growth 116 TABLE 73 GERMANY: MACROECONOMIC INDICATORS 117 TABLE 74 GERMANY: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 117 TABLE 75 GERMANY: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 117 11.3.3 FRANCE 118 11.3.3.1 Increasing healthcare expenditure to support particle therapy product adoption 118 TABLE 76 FRANCE: MACROECONOMIC INDICATORS 118 TABLE 77 FRANCE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 119 TABLE 78 FRANCE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 119 11.3.4 UK 119 11.3.4.1 Increasing acceptance of particle therapy techniques in cancer treatment to support market growth 119 TABLE 79 UK: MACROECONOMIC INDICATORS 120 TABLE 80 UK: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 120 TABLE 81 UK: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 121 11.3.5 ITALY 121 11.3.5.1 Increasing awareness activities to support market growth 121 TABLE 82 ITALY: MACROECONOMIC INDICATORS 121 TABLE 83 ITALY: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 122 TABLE 84 ITALY: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 122 11.3.6 SPAIN 122 11.3.6.1 Increasing number of conferences and government funding for cancer research to drive market 122 TABLE 85 SPAIN: MACROECONOMIC INDICATORS 123 TABLE 86 SPAIN: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 124 TABLE 87 SPAIN: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 124 11.3.7 REST OF EUROPE 124 TABLE 88 REST OF EUROPE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 125 TABLE 89 REST OF EUROPE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 125 11.4 ASIA PACIFIC 125 11.4.1 ASIA PACIFIC: RECESSION IMPACT 126 FIGURE 33 ASIA PACIFIC: PARTICLE THERAPY MARKET SNAPSHOT 127 TABLE 90 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128 TABLE 91 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 128 TABLE 92 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 128 TABLE 93 ASIA PACIFIC: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 129 TABLE 94 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION) 129 TABLE 95 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION) 129 TABLE 96 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 130 11.4.2 JAPAN 130 11.4.2.1 Increasing use of heavy ion therapy for cancer treatment to propel market 130 TABLE 97 JAPAN: MACROECONOMIC INDICATORS 131 TABLE 98 JAPAN: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 131 TABLE 99 JAPAN: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 131 11.4.3 CHINA 132 11.4.3.1 High cancer burden to drive market 132 TABLE 100 CHINA: MACROECONOMIC INDICATORS 132 TABLE 101 CHINA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 133 TABLE 102 CHINA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 133 11.4.4 INDIA 133 11.4.4.1 Improving research capabilities to support market growth 133 TABLE 103 INDIA: MACROECONOMIC INDICATORS 134 TABLE 104 INDIA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 134 TABLE 105 INDIA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 134 11.4.5 AUSTRALIA 135 11.4.5.1 Healthcare funding availability to boost market growth 135 TABLE 106 AUSTRALIA: MACROECONOMIC INDICATORS 135 TABLE 107 AUSTRALIA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 135 TABLE 108 AUSTRALIA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 136 11.4.6 SOUTH KOREA 136 11.4.6.1 Rising prevalence of cancer to drive market 136 TABLE 109 SOUTH KOREA: MACROECONOMIC INDICATORS 137 TABLE 110 SOUTH KOREA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 137 TABLE 111 SOUTH KOREA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 137 11.4.7 REST OF ASIA PACIFIC 138 TABLE 112 REST OF ASIA PACIFIC: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 138 TABLE 113 REST OF ASIA PACIFIC: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 138 11.5 LATIN AMERICA 139 11.5.1 LATIN AMERICA: RECESSION IMPACT 139 TABLE 114 LATIN AMERICA: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 139 TABLE 115 LATIN AMERICA: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 140 TABLE 116 LATIN AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 140 TABLE 117 LATIN AMERICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 140 TABLE 118 LATIN AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION) 141 TABLE 119 LATIN AMERICA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION) 141 TABLE 120 LATIN AMERICA: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 141 11.5.2 BRAZIL 142 11.5.2.1 Government initiates to propel market growth 142 TABLE 121 BRAZIL: MACROECONOMIC INDICATORS 142 TABLE 122 BRAZIL: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 143 TABLE 123 BRAZIL: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 143 11.5.3 MEXICO 143 11.5.3.1 Growing adoption of advanced medical technologies to drive market 143 TABLE 124 MEXICO: MACROECONOMIC INDICATORS 144 TABLE 125 MEXICO: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 144 TABLE 126 MEXICO: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 144 11.5.4 REST OF LATIN AMERICA 145 TABLE 127 REST OF LATIN AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 145 TABLE 128 REST OF LATIN AMERICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 145 11.6 MIDDLE EAST & AFRICA 146 11.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET 146 11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 146 TABLE 129 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 147 TABLE 130 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 147 TABLE 131 MIDDLE EAST & AFRICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 147 TABLE 132 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION) 148 TABLE 133 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION) 148 TABLE 134 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 148 12 COMPETITIVE LANDSCAPE 149 12.1 OVERVIEW 149 12.2 STRATEGIES ADOPTED BY KEY PLAYERS 150 FIGURE 34 KEY DEVELOPMENTS IN PARTICLE THERAPY MARKET 150 12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 151 FIGURE 35 REVENUE ANALYSIS OF TOP PLAYERS IN PARTICLE THERAPY MARKET 151 12.4 MARKET SHARE ANALYSIS 152 FIGURE 36 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022 152 12.5 COMPANY EVALUATION MATRIX 153 12.5.1 STARS 153 12.5.2 EMERGING LEADERS 153 12.5.3 PERVASIVE PLAYERS 153 12.5.4 PARTICIPANTS 153 FIGURE 37 PARTICLE THERAPY MARKET: COMPANY EVALUATION MATRIX, 2022 154 12.6 COMPETITIVE BENCHMARKING FOR KEY PLAYERS 155 12.6.1 PARTICLE THERAPY MARKET: COMPANY FOOTPRINT 155 TABLE 135 OVERALL COMPANY FOOTPRINT (10 COMPANIES) 155 TABLE 136 TYPE FOOTPRINT (10 COMPANIES) 155 TABLE 137 PRODUCT & SERVICE FOOTPRINT (10 COMPANIES) 156 TABLE 138 SYSTEM FOOTPRINT (10 COMPANIES) 157 TABLE 139 CANCER TYPE FOOTPRINT (10 COMPANIES) 157 TABLE 140 APPLICATION FOOTPRINT (10 COMPANIES) 158 TABLE 141 REGIONAL FOOTPRINT (10 COMPANIES) 159 12.7 STARTUP/SME EVALUATION MATRIX 160 12.7.1 PROGRESSIVE COMPANIES 160 12.7.2 RESPONSIVE COMPANIES 160 12.7.3 DYNAMIC COMPANIES 160 12.7.4 STARTING BLOCKS 160 FIGURE 38 PARTICLE THERAPY MARKET: STARTUP/SME EVALUATION MATRIX, 2022 161 12.7.5 COMPETITIVE BENCHMARKING FOR STARTUPS/SMES 162 TABLE 142 OVERALL COMPANY FOOTPRINT 162 TABLE 143 TYPE FOOTPRINT 162 TABLE 144 PRODUCT & SERVICE FOOTPRINT 162 TABLE 145 SYSTEM FOOTPRINT 163 TABLE 146 CANCER TYPE FOOTPRINT 163 TABLE 147 APPLICATION FOOTPRINT 163 TABLE 148 REGIONAL FOOTPRINT 163 12.8 COMPETITIVE SCENARIOS & TRENDS 164 12.8.1 PRODUCT LAUNCHES & APPROVALS 164 TABLE 149 PARTICLE THERAPY MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020−AUGUST 2023) 164 12.8.2 DEALS 164 TABLE 150 PARTICLE THERAPY MARKET: DEALS (JANUARY 2020−AUGUST 2023) 164 12.8.3 OTHER DEVELOPMENTS 166 TABLE 151 PARTICLE THERAPY MARKET: OTHER DEVELOPMENTS (JANUARY 2020−AUGUST 2023) 166 13 COMPANY PROFILES 167 13.1 KEY PLAYERS 167 (Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)* 13.1.1 IBA WORLDWIDE 167 TABLE 152 IBA WORLDWIDE: BUSINESS OVERVIEW 167 FIGURE 39 IBA WORLDWIDE: COMPANY SNAPSHOT (2022) 168 13.1.2 VARIAN MEDICAL SYSTEMS, INC. 172 TABLE 153 VARIAN MEDICAL SYSTEMS, INC.: BUSINESS OVERVIEW 172 FIGURE 40 VARIAN MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2022) 173 13.1.3 HITACHI, LTD. 176 TABLE 154 HITACHI, LTD.: BUSINESS OVERVIEW 176 FIGURE 41 HITACHI, LTD.: COMPANY SNAPSHOT (2021) 177 13.1.4 MEVION MEDICAL SYSTEMS 179 TABLE 155 MEVION MEDICAL SYSTEMS: BUSINESS OVERVIEW 179 13.1.5 SUMITOMO HEAVY INDUSTRIES LTD. 182 TABLE 156 SUMITOMO HEAVY INDUSTRIES LTD.: BUSINESS OVERVIEW 182 FIGURE 42 SUMITOMO HEAVY INDUSTRIES LTD.: COMPANY SNAPSHOT (2021) 183 13.1.6 PROVISION HEALTHCARE, LLC 185 TABLE 157 PROVISION HEALTHCARE, LLC: BUSINESS OVERVIEW 185 13.1.7 TOSHIBA MEDICAL SYSTEMS CORPORATION 186 TABLE 158 TOSHIBA MEDICAL SYSTEMS CORPORATION: BUSINESS OVERVIEW 186 FIGURE 43 TOSHIBA MEDICAL SYSTEMS CORPORATION: COMPANY SNAPSHOT (2022) 187 13.1.8 OPTIVUS PROTON THERAPY, INC. 188 TABLE 159 OPTIVUS PROTON THERAPY, INC.: BUSINESS OVERVIEW 188 13.1.9 PROTOM INTERNATIONAL, INC. 189 TABLE 160 PROTOM INTERNATIONAL, INC.: BUSINESS OVERVIEW 189 13.1.10 ADVANCED ONCOTHERAPY PLC 190 TABLE 161 ADVANCED ONCOTHERAPY PLC: BUSINESS OVERVIEW 190 13.2 OTHER PLAYERS 191 13.2.1 DANFYSIK A/S 191 TABLE 162 DANFYSIK A/S: BUSINESS OVERVIEW 191 13.2.2 P-CURE, LTD. 192 TABLE 163 P-CURE, LTD.: BUSINESS OVERVIEW 192 13.2.3 PTW FREIBURG GMBH 193 TABLE 164 PTW FREIBURG GMBH: BUSINESS OVERVIEW 193 *Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies. 14 APPENDIX 194 14.1 DISCUSSION GUIDE 194 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 199 14.3 CUSTOMIZATION OPTIONS 201 14.4 RELATED REPORTS 201 14.5 AUTHOR DETAILS 202
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療機器)の最新刊レポート
MarketsandMarkets社のMedical Devices分野での最新刊レポート
本レポートと同じKEY WORD(pediatric)の最新刊レポート
よくあるご質問MarketsandMarkets社はどのような調査会社ですか?マーケッツアンドマーケッツ(MarketsandMarkets)は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/15 10:26 157.84 円 166.62 円 202.61 円 |